- Home
- Features
- News
- Topics
- Labor
- Management
- Opinions/Blogs
- Tools & Resources
ZURICH (Reuters) – Johnson & Johnson declared its $30 billion tender offer for Swiss biotechnology company Actelion successful on Friday, reporting it controlled 77.2 percent of the voting rights after the main offer period.
Source:: J&J declares Actelion tender offer a success, sees closing in second quarter